Float Short %

17.3

Margin Of Safety %

Put/Call OI Ratio

0.12

EPS Next Q Diff

-1.62

EPS Last/This Y

-0.28

EPS This/Next Y

-0.22

Price

7.97

Target Price

33.11

Analyst Recom

1.45

Performance Q

-24.33

Relative Volume

0.54

Beta

Ticker: FDMT

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	FDMT	7.97	0.11	0.00	4726
2025-12-29	FDMT	7.67	0.11	0.00	4744
2025-12-30	FDMT	7.58	0.11	0.20	4752
2025-12-31	FDMT	7.48	0.11	160.00	4761
2026-01-02	FDMT	7.31	0.14	0.59	4909
2026-01-05	FDMT	7.31	0.15	0.04	4903
2026-01-06	FDMT	7.18	0.14	999.99	5097
2026-01-07	FDMT	7.78	0.14	1.25	5109
2026-01-08	FDMT	7.3	0.14	2.33	5107
2026-01-09	FDMT	7.51	0.15	0.40	5158
2026-01-12	FDMT	7.52	0.15	0.00	5162
2026-01-13	FDMT	7.87	0.15	0.27	5162
2026-01-14	FDMT	8.76	0.15	0.09	5112
2026-01-15	FDMT	7.61	0.16	0.02	4878
2026-01-16	FDMT	7.53	0.16	0.04	5027
2026-01-20	FDMT	7.63	0.17	0.00	1842
2026-01-21	FDMT	7.68	0.12	0.19	2472
2026-01-22	FDMT	8.1	0.12	0.00	2593
2026-01-23	FDMT	7.96	0.12	0.88	2601
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	FDMT	7.98	41.3	-	-3.26
2025-12-29	FDMT	7.67	41.3	-	-3.26
2025-12-30	FDMT	7.60	41.3	-	-3.26
2025-12-31	FDMT	7.48	41.3	-	-3.26
2026-01-02	FDMT	7.32	41.3	-	-3.26
2026-01-05	FDMT	7.30	41.3	-	-3.26
2026-01-06	FDMT	7.19	41.3	-	-3.26
2026-01-07	FDMT	7.78	41.3	-	-3.26
2026-01-08	FDMT	7.30	41.3	-	-3.26
2026-01-09	FDMT	7.52	41.3	-	-3.26
2026-01-12	FDMT	7.51	41.3	-	-3.26
2026-01-13	FDMT	7.88	41.3	-	-3.26
2026-01-14	FDMT	8.76	41.3	-	-3.26
2026-01-15	FDMT	7.61	41.3	-	-3.26
2026-01-16	FDMT	7.53	41.3	-	-3.26
2026-01-20	FDMT	7.63	41.3	-	-3.26
2026-01-21	FDMT	7.69	41.3	-	-3.26
2026-01-22	FDMT	8.11	41.3	-	-3.26
2026-01-23	FDMT	7.97	41.3	-	-3.26
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	FDMT	-0.25	-1.48	9.66
2025-12-29	FDMT	-0.25	-1.48	9.66
2025-12-30	FDMT	-0.25	-1.48	9.66
2025-12-31	FDMT	-0.25	-1.48	9.66
2026-01-02	FDMT	-0.25	-1.48	9.66
2026-01-05	FDMT	-0.25	-1.45	9.66
2026-01-06	FDMT	-0.25	-1.45	9.66
2026-01-07	FDMT	-0.25	-1.45	9.66
2026-01-08	FDMT	-0.25	-1.45	9.66
2026-01-09	FDMT	-0.25	-1.45	9.66
2026-01-12	FDMT	-0.26	-1.45	9.66
2026-01-13	FDMT	-0.25	-1.45	16.68
2026-01-14	FDMT	-0.25	-1.45	16.68
2026-01-15	FDMT	-0.25	-1.45	16.68
2026-01-16	FDMT	-0.25	-1.45	16.68
2026-01-20	FDMT	-0.25	-2.05	16.68
2026-01-21	FDMT	-0.25	-2.05	16.68
2026-01-22	FDMT	-0.25	-2.05	17.30
2026-01-23	FDMT	-0.25	-2.05	17.30
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.69

Avg. EPS Est. Current Quarter

-0.53

Avg. EPS Est. Next Quarter

-0.93

Insider Transactions

-0.25

Institutional Transactions

-2.05

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

85.5

Max Drawdown 5-Year %

-95.2

Target Price

33.11

P/E

Forward P/E

PEG

P/S

3789.97

P/B

1.01

P/Free Cash Flow

EPS

-3.94

Average EPS Est. Cur. Y

-3.26

EPS Next Y. (Est.)

-3.48

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-174314.17

Relative Volume

0.54

Return on Equity vs Sector %

-84

Return on Equity vs Industry %

-68

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

4D Molecular Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 227

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in EmeryVille, California.

stock quote shares FDMT. – 4D Molecular Therapeutics Inc Stock Price stock today

news today FDMT. – 4D Molecular Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch FDMT. – 4D Molecular Therapeutics Inc yahoo finance google finance

stock history FDMT. – 4D Molecular Therapeutics Inc invest stock market

stock prices FDMT premarket after hours

ticker FDMT fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: FDMT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y